| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 11/15/2001 | US20010041815 Psychological disorders |
| 11/15/2001 | US20010041809 Novel forms of pravastatin sodium |
| 11/15/2001 | US20010041799 Diephenyl carbocyclic thioamide derivatives |
| 11/15/2001 | US20010041747 S(+) desmethylselegiline and its use to treat immune system dysfunction |
| 11/15/2001 | US20010041746 Reduce side effect; analgesics |
| 11/15/2001 | US20010041745 Administering a triphenylethylene compound |
| 11/15/2001 | US20010041744 Vision defects |
| 11/15/2001 | US20010041743 Prostaglandins |
| 11/15/2001 | US20010041741 Composition for improvement of cellular nutrition and mitochondrial energetics |
| 11/15/2001 | US20010041739 Use of PDE-4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection |
| 11/15/2001 | US20010041736 Therapy for nervous system disorders |
| 11/15/2001 | US20010041735 Amino ceramide - like compounds and therapeutic methods of use |
| 11/15/2001 | US20010041734 Administering nefiracetam |
| 11/15/2001 | US20010041733 Alopecia therapy |
| 11/15/2001 | US20010041732 Use |
| 11/15/2001 | US20010041731 To inhibit, modulate, attenuate, or prevent cell-cycle progression, intracellular signalling, or cell proliferation |
| 11/15/2001 | US20010041729 Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure |
| 11/15/2001 | US20010041727 Use of pramipexole for the treatment of addictive disorders |
| 11/15/2001 | US20010041726 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 11/15/2001 | US20010041723 Using agonists and antagonists of the nicotinergic acetylcholine receptors of insects such as fleas, lice and flies, on humans and animals |
| 11/15/2001 | US20010041722 Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
| 11/15/2001 | US20010041720 2-Amino-N-((1R)-2-((3R)-3-benzyl-3-(N,N',N' -trimethylhydrazinocarbonyl)piperidin-1-yl)-1-(1H-indol-3-ylmethyl)-2 -oxoethyl)-2-methylpropionamide; increasing rate and extent of growth, milk and wool production |
| 11/15/2001 | US20010041719 The use of R (+)-alpha- (2,3-Dimethoxyphenyl) -1- [ 2- (4-fluorophenyl) ethyl] -4-piper idinemethanol for the treatment of sleep disorders |
| 11/15/2001 | US20010041718 Cis-6-(4-fluoro-phenyl)-5-(4-(2-piperidin-1-yl-ethoxy)-phenyl) -5,6,7,8-tetrahydronaphthalene-2-ol, for example, and other estrogen agonists/antagonists to treat rheumatoid arthritis, colon cancer, wounds, cataracts and skin wrinkles |
| 11/15/2001 | US20010041717 Chronic, bolus administration of D-threo methylphenidate |
| 11/15/2001 | US20010041716 Compositions and methods for locally treating inflammatory diseases |
| 11/15/2001 | US20010041715 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
| 11/15/2001 | US20010041713 Cyclooxygenase-2 (COX-2); administering 2-(2-methylpyrid-5-yl),3-(p-methylsulfonylphenyl),5-chloro-pyridine, or salt, hydrate or N-oxide thereof, alone or in combination with other drugs |
| 11/15/2001 | US20010041712 Synergistic mixture for treatment of solid tumors; irinotecan (CPT-11) and cisplatin, for example |
| 11/15/2001 | US20010041711 8-(4,4-Bis(p-fluorophenyl)butyl)-1-phenyl-1,3,8-triazospiro(4.5) decan-4-one, for example; treating pain with reduced side effects of opioid analgesics; affinity for opioid receptor-like (ORL1) receptor |
| 11/15/2001 | US20010041710 (4R)-1-(4-(4-Fluorophenoxy)benzyl)-2-oxo-imidazolidine-4 -carboxylic acid hydroxyamide, for example; treating various diseases including osteoarthritis, rheumatoid arthritis, cancer, osteoporosis, strokes |
| 11/15/2001 | US20010041706 By administering a CYP3A4 inhibitor and a CYP2C8 inhibitor, CYP3A4 represents 25% of all cytochrome P450's in the human liver and CYP2C8 is the major pathway of paclitaxel inactivation; reduce taxane pharmacokinetic variability |
| 11/15/2001 | US20010041705 Heterocyclic carboxamides |
| 11/15/2001 | US20010041703 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair |
| 11/15/2001 | US20010041699 Method for treating osteoporosis in castrated prostatic cancer patients |
| 11/15/2001 | US20010041698 Use of 5alpha -androst-1-en-3,17-dione to increase the level of the anabolic/androgenic hormone 17beta-hydroxy-5alpha-androst-1-en-3-one in humans |
| 11/15/2001 | US20010041697 Implanting in an animal an effective amount of melengestrol acetate and trenbolone acetate for increasing growth performance, suppressing estrus and preventing pregnancy in an animal prefererably heifer |
| 11/15/2001 | US20010041696 Cosmetic or dermatological use of 7-hydroxylated steroids |
| 11/15/2001 | US20010041695 Orally administering to a post-menopausal woman a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of L-carnitine or salts |
| 11/15/2001 | US20010041692 Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use |
| 11/15/2001 | US20010041691 (Dihydrogen phosphonoxy)alkyloxy containing a triazole derivative used as antifungal agent |
| 11/15/2001 | US20010041689 Bisphosphonate conjugates and methods of making and using the same |
| 11/15/2001 | US20010041688 Methods and compositions for the regulation of vasoconstriction |
| 11/15/2001 | US20010041687 Administering an effective amount of a flavone 8-carboxylic acid to a mammal suffering from a vascular or cardiovascular or acute coronary syndromes alone or with thromolytic, anticoagulants, antithrombotic or antiplatelet agents |
| 11/15/2001 | US20010041686 Novel therapeutic application of enoxaparin |
| 11/15/2001 | US20010041685 Mucin synthesis inhibitors |
| 11/15/2001 | US20010041683 Extracting polar lipid from a cocoa material to obtain crude sphingolipid containing extract, hydrolyzing crude sphinolipid containing extract with a base, removing the products of base hydrolysis; anticarcinogenic agents |
| 11/15/2001 | US20010041682 Purine or pyrimidine containing dinucleotide derivatives useful for hydrating mucous secretions in the lungs of a patient in need of such a treatment |
| 11/15/2001 | US20010041681 Therapeutically useful synthetic oligonucleotides |
| 11/15/2001 | US20010041680 Administering an antibody that specifically binds to EMAP(endothelial monocyte-activating polypeptides II) to the subject which needs inhibition of EMAP activity in an amount effective to stimulate vascular growth in cardiac muscle |
| 11/15/2001 | US20010041678 Consists of N-chlorophenylcarbamates and N-chlorophenylthiocarbamates along with chemotherapeutic agent; anticancer and antitumor agents |
| 11/15/2001 | US20010041676 Systemic, transdermal, intranasal or inhalation administration of a glucocorticosteroid in the form of glucosides or orthoester glucoside to treat adrenal insufficiency, inflammatory or immune system diseases |
| 11/15/2001 | US20010041675 Satisfy composition and method of weight control |
| 11/15/2001 | US20010041673 A purine derivative or salt, useful for treating heart related diseases including congestive heart failure in mammals, particularly in human |
| 11/15/2001 | US20010041672 Luteinizing hormone releasing hormone analogs or a combination with antiestrogen which is selected from raloxifen, droloxifen, centchroman or derivatives, useful for treating endometrioses and myomas ( gynecological conditions) |
| 11/15/2001 | US20010041671 Ophthalmic formulations |
| 11/15/2001 | US20010041194 Mixture with oil and wax |
| 11/15/2001 | US20010041193 Mixture of ascorbic acid, zinc salt and tyrosine compound |
| 11/15/2001 | US20010041191 Magnesium lactate, magnesium asparate, magnesium acetate, magnesium pyrophosphate |
| 11/15/2001 | US20010041189 Dipeptide containing glutamic acid |
| 11/15/2001 | US20010041186 Composition and method for acceleration of wound and burn healing |
| 11/15/2001 | US20010041182 Stable activity antioxidant provitamin such as l-ascorbic acid-2-phosphate and alpha-tocopheryl phosphate |
| 11/15/2001 | US20010041178 Preventing airway mucus production by administration of EGF-R antagonists |
| 11/15/2001 | US20010041177 Biomarker molecule CD163, antibody complex |
| 11/15/2001 | US20010041171 Polymer with pendant acid functional groups; will not degrade in the gastrointestinal tract |
| 11/15/2001 | US20010041170 Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury |
| 11/15/2001 | US20010041165 Effervescent bisphosphonate formulation |
| 11/15/2001 | US20010041164 Pharmaceutical preparation for inhalation of an opioid |
| 11/15/2001 | US20010041163 Xanthene dye structure with a hydrophilic and lipophilic group bound to the same carbon, ultrasonic |
| 11/15/2001 | DE10100445A1 Treating digestive disorders, excessive mucus formation in upper respiratory tract and/or hemorrhoids, by topical application of analgesic to acupuncture points of the hand |
| 11/15/2001 | DE10045904A1 Retard alpha-lipoic acid composition based on cationogenic polymer carrier, especially chitosan, useful as a food supplement, medicament or cosmetic |
| 11/15/2001 | DE10022925A1 New indole-carboxamide or azepino-indole derivatives and analogs, are poly-ADP ribose polymerase inhibitors useful e.g. for treating neurodegenerative disease, ischemia, epilepsy, tumors, sepsis or diabetes mellitus |
| 11/15/2001 | DE10022856A1 Treating central nervous system disorders e.g. cognitive deficiency or depression, using combination of lipoic acid and C-1 donor e.g. S-adenosyl-methionine |
| 11/15/2001 | DE10022616A1 Inhibiting growth of microrganisms causing body odor, skin or nail mycosis or dandruff, using 6,10-dimethyl-5,9-undecadien-2-ol as potent, well tolerated antimicrobial agent |
| 11/15/2001 | DE10022518A1 Preparation of L-ascorbic acids by reacting 2-keto-L-gulonic acids or melt of 2-keto-L-gulonic acid alkyl esters under acid catalysis using water-miscible solvent(s) |
| 11/15/2001 | DE10022510A1 Composition used as folate source in food, feed, nutritional supplements or medicaments, e.g. for prophylaxis of cardiovascular disease includes folic acid and 5-methyl-tetrahydrofolic acid |
| 11/15/2001 | DE10021731A1 Cyclipostine, Verfahren zu ihrer Herstellung und Verwendung derselben Cyclipostins, processes for their preparation and use thereof |
| 11/15/2001 | DE10021618A1 Drug preparation or foodstuff for treating inflammatory bowel disease or pouchitis in colectomy patients, contains 4-aminoacyloxyalkyl-2-oxetanone derivative such as orlistat |
| 11/15/2001 | CA2691739A1 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo [b]thiophene and salts thereof |
| 11/15/2001 | CA2409759A1 Method and composition for the treatment of angiogenesis |
| 11/15/2001 | CA2409758A1 Novel multicyclic compounds and the use thereof |
| 11/15/2001 | CA2409729A1 5-ht7 receptor antagonists |
| 11/15/2001 | CA2409720A1 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| 11/15/2001 | CA2409679A1 Bacterial carboxypeptidase cpg2 variants and their use in gene directed enzyme prodrug therapy |
| 11/15/2001 | CA2409461A1 Evaporative coolant comprising hydrofluorocarbons and/or hydrochlorofluorocarbons |
| 11/15/2001 | CA2409150A1 Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
| 11/15/2001 | CA2408935A1 Method of treating immune pathologies with low dose estrogen |
| 11/15/2001 | CA2408889A1 Immunosuppressive compositions |
| 11/15/2001 | CA2408818A1 Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with ns398 or pdtc |
| 11/15/2001 | CA2408751A1 2-substituted pregna-1, 3, 5 (10) -triene and chola-1, 3, 5 (10)-triene derivatives and their biological activity |
| 11/15/2001 | CA2408732A1 Modified es cells and es cell-specific gene |
| 11/15/2001 | CA2408666A1 Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system |
| 11/15/2001 | CA2408647A1 Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases |
| 11/15/2001 | CA2408622A1 Methods for inhibiting proliferation and inducing apoptosis in cancer cells |
| 11/15/2001 | CA2408571A1 Mammalian receptor proteins; related reagents and methods |
| 11/15/2001 | CA2408563A1 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof |
| 11/15/2001 | CA2408544A1 Combined marine and plant extract compositions |
| 11/15/2001 | CA2408486A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 11/15/2001 | CA2408453A1 Uridine derivatives as antibiotics |
| 11/15/2001 | CA2408448A1 Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation |